The ASCO Annual Meeting is being held June 2 to 6. A study presented today shows that removing radiation therapy from the treatment plan for an aggressive form of lymphoma does not impact the risk of recurrence or overall survival. Read More >>
meetings
June 6, 2023 · ASCO Staff
June 5, 2023 · ASCO Staff
The ASCO Annual Meeting is being held June 2 to 6. Research highlights from the day include using trastuzumab deruxtecan to treat HER2-expressing tumors and using CAR T-cell therapy to slow or stop multiple myeloma. Read More >>
June 4, 2023 · ASCO Staff
The ASCO Annual Meeting is being held June 2 to 6. Several notable studies will be presented today. Topics include radiation therapy in rectal cancer, osimertinib for lung cancer, vorasidenib for grade 2 glioma, nivolumab for Hodgkin lymphoma, and mirvetuximab soravtansine for ovarian cancer. Read More >>
June 3, 2023 · ASCO Staff
The ASCO Annual Meeting is being held June 2 to 6. A study that will be presented today explores combining immunotherapy and targeted therapy to reduce the risk of death and recurrence for people with advanced ovarian cancer. Read More >>
June 2, 2023 · ASCO Staff
The ASCO Annual Meeting is being held June 2 to 6, and here is some of the notable research that will be presented today. This research explores using less extensive surgery for cervical cancer and using targeted therapy to reduce the risk of breast cancer recurrence. Read More >>